Prostate Cancer Hormone Therapy: How Low Does PSA Actually Go? (2026 Update)

Hormone therapy works by blocking male hormones to lower PSA levels, but how far it drops is not a fixed target — it varies depending on treatment response and disease stage. While the source notes do not specify an exact lower-bound PSA figure, they clearly confirm that PSA remains the key indicator for follow-up monitoring.

Key Takeaways

• Hormone therapy is the backbone of treatment for metastatic prostate cancer, and in high-risk or locally advanced disease, standard practice includes combining it with radiation therapy for several years.
• Prostate cancer follow-up centers on PSA levels: for patients who had surgery, the focus is on whether PSA drops to a nearly undetectable level, while for patients who had radiation therapy, the focus is on whether PSA gradually declines and stays at its lowest point (nadir).
• If hormone therapy stops working, other drug classes, chemotherapy, or PSMA-targeted radioligand therapy may be considered.
• PSA testing is easy to obtain in any country, making it convenient to continue after returning home. A handover document noting the timing of the next test and target range can be provided (remote review fee KRW 1,000,000, about US$730, deducted if a treatment contract is signed).
• As with survival rates, individual variation in PSA response can be substantial, and the duration and method of hormone therapy must always be decided in consultation with your medical team.

How Far Can PSA Drop with Hormone Therapy?

• The note does not provide a specific numeric target (such as a lower-bound value in ng/mL). What is confirmed is that PSA generally tends to respond by decreasing, and that the way this response is assessed differs by stage.
• For patients who had surgery, follow-up focuses on whether PSA falls to a nearly undetectable level. For patients who had radiation therapy (including those receiving concurrent hormone therapy), the focus is on whether PSA gradually declines and remains at its lowest point.
• In metastatic disease, hormone therapy is described as the core of treatment, and it has become standard to combine it from the start with a stronger anti-androgen agent or chemotherapy. This stage is not aimed at cure but at long-term control.

What Is the Order of PSA Monitoring and Management?

• Step 1 — Before treatment, risk group is determined using PSA, MRI, and biopsy (Gleason score).
• Step 2 — Depending on risk group, surgery, radiation, or hormone therapy is started alone or in combination.
• Step 3 — In the first few years after treatment, PSA is checked every few months to see whether it is undetectable (surgery group) or staying at its nadir (radiation group).
• Step 4 — Once levels stabilize, testing intervals are lengthened. For patients on hormone therapy, bone density, blood sugar, lipids, and cardiac risk are also monitored.
• Step 5 — If PSA rises again, imaging is used to locate the site of recurrence, and if hormone therapy is no longer effective, other drug classes, chemotherapy, or PSMA-targeted therapy are considered.

What Side Effects Can Occur During Hormone Therapy?

• Hormone therapy can be accompanied by changes such as hot flashes, reduced libido, fatigue, loss of muscle mass with increased body fat, and reduced bone density, so exercise and bone density testing are generally recommended alongside treatment.
• The degree of these changes varies by individual and can also differ depending on the type of medication (injection or oral) and any other concurrent treatments (such as radiation or chemotherapy).

FAQ — If PSA Rises Again, Does That Mean Treatment Has Failed?

A rising PSA is regarded as a signal suggestive of recurrence, leading to imaging tests to locate where the recurrence has occurred — it does not immediately mean the treatment has failed. From there, the next options considered may include other drug classes, chemotherapy, or radioligand therapy (PSMA-targeted).

FAQ — How Long Does Hormone Therapy Need to Continue?

When combined with radiation therapy in high-risk or locally advanced disease, hormone therapy lasting several years is described as part of the standard approach. In metastatic disease, it is often continued long-term as the central axis of treatment. The exact duration depends on risk group, stage, coexisting conditions, and treatment response, so it should be discussed with your medical team.

Sources and Notes

• This article was written based on prostate cancer notes (National Cancer Registration Statistics 2019–2023, Korea Central Cancer Registry, National Cancer Center Korea; NCCN patient guidelines; SEER 2016–2022).
• This content is provided for general medical information purposes, and actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment should always be determined through consultation with your medical team.